Studies conducted in breast and prostate cancer undergoing hormone therapy reported an increased risk of NAFLD, including aromatase inhibitors (HR: 15.92; 95% CI, 6.56–38.63; p = 0.0001) [32] and ADT (HR: 1.54, 95% CI, 1.40–1.68, p < 0.001) [28], respectively. The gene discussed is CYP19A1; the disease is metabolic dysfunction-associated steatotic liver disease.